Recently, several clinical trials with SGLT2 inhibitors have shownthat they reduce heart failure (HF) hospitalization as well as cardiovascular death and majoradverse cardiovascular events in patients with T2DM at high cardiovascular risk[22, 23, 24, 25, 26, 27] (Table 1). The gene discussed is SLC5A2; the disease is hydrops fetalis.